Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other rare diseases. The company's lead candidate, CAP-1002, is an allogeneic cardiosphere-derived cell therapy in late-stage development for DMD cardiomyopathy, with the HOPE-3 pivotal trial recently completed. The 300%+ 3-month stock surge reflects positive clinical momentum and potential near-term regulatory catalysts.
Capricor operates as a development-stage biotech with no product revenue. The company funds operations through equity raises and grant funding while advancing CAP-1002 through clinical trials. Value creation depends on successful FDA approval, which would enable either direct commercialization (requiring significant capital for sales infrastructure) or out-licensing/partnership deals with larger pharma companies for milestone payments and royalties. DMD affects approximately 1 in 3,500-5,000 male births globally, representing a defined orphan drug market with premium pricing potential if efficacy is demonstrated. The negative gross margin reflects R&D expenses without offsetting revenue.
CAP-1002 clinical trial data readouts and regulatory milestone announcements (FDA interactions, BLA submissions)
Partnership or licensing deal announcements with major pharmaceutical companies
Equity financing announcements (dilutive capital raises to fund operations)
Competitive developments in DMD treatment landscape (competitor trial results, FDA approvals)
Cash runway updates and going-concern assessments
Binary regulatory risk - FDA rejection or clinical trial failure would eliminate near-term value given single lead asset concentration
Orphan drug market size constraints - DMD cardiomyopathy addressable market may be 2,000-4,000 patients in US, limiting peak revenue potential even with approval
Reimbursement uncertainty for novel cell therapies - payers increasingly scrutinizing high-cost rare disease treatments despite orphan drug pricing flexibility
Sarepta Therapeutics and other established DMD players have gene therapy and exon-skipping approaches with earlier market entry and established relationships
Larger biotechs (Pfizer, Roche) developing competing DMD cardiac therapies with superior capital resources for trials and commercialization
Technology risk - exosome and cell therapy platforms face manufacturing scalability challenges and potential immunogenicity issues
Cash burn risk - negative $15-20M annual operating cash flow with $1B market cap suggests potential near-term dilutive financing if regulatory timelines extend
Going concern risk if clinical setbacks occur - limited revenue diversification means single trial failure could trigger liquidity crisis
Equity dilution risk - pre-revenue biotechs typically require multiple financing rounds, with current shareholders facing 30-50% dilution risk through commercialization
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, biotech sector sentiment and risk appetite correlate with broader equity markets. Patient enrollment can be affected by healthcare system capacity during economic stress, but DMD is a severe progressive disease where treatment decisions are less discretionary.
Rising rates create significant headwinds through two channels: (1) Higher discount rates compress NPV of distant future cash flows, disproportionately impacting pre-revenue biotechs with 3-5+ year monetization timelines, and (2) Reduced risk appetite shifts capital away from speculative growth stocks toward safer yield alternatives. The company's 3.59x current ratio provides liquidity buffer, but future financing costs increase in higher rate environments.
Minimal direct credit exposure given pre-revenue status and low debt/equity ratio of 0.17. However, access to capital markets is critical - tightening credit conditions reduce biotech IPO/follow-on activity and increase equity dilution required for financing. Venture capital and institutional biotech investment flows are highly sensitive to credit market conditions.
growth/momentum - The 300% 3-month return and 52% 1-year return attract speculative biotech investors focused on binary clinical/regulatory catalysts rather than fundamental cash flow analysis. High volatility and pre-revenue status appeal to risk-tolerant growth investors, venture-style healthcare funds, and momentum traders riding clinical trial newsflow. Not suitable for value or income investors given negative margins and no dividend potential.
high - Clinical-stage single-asset biotechs exhibit extreme volatility with 50-80% single-day moves common on trial data releases. Beta likely exceeds 2.0x relative to broader market. The recent 300% surge demonstrates characteristic biotech momentum, but downside risk is equally severe if clinical or regulatory setbacks occur.
